Covered recipient · General Payments record
KATY MILLER
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2022–2024
$1,238.04
- Reported across 22 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $784.11 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $236.51 | 2 |
| Teva Pharmaceuticals USA, Inc. | $123.15 | 1 |
| Janssen Pharmaceuticals, Inc | $116.74 | 1 |
| Astellas Pharma US Inc | $115.08 | 1 |
| ABBVIE INC. | $56.06 | 3 |
| Amgen Inc. | $43.86 | 2 |
| Novo Nordisk AS | $35.69 | 2 |
| Xeris Pharmaceuticals, Inc. | $21.91 | 1 |
| GlaxoSmithKline, LLC. | $20.22 | 1 |
| Merck Sharp & Dohme Corporation | $14.89 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $20.22 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107665026 | CMS |
| ABBVIE INC. | $22.14 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107665028 | CMS |
| ABBVIE INC. | $13.70 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107665030 | CMS |
| Amgen Inc. | $21.27 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117630446 | CMS |
| Amgen Inc. | $22.59 | 06/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117630448 | CMS |
| Astellas Pharma US Inc | $115.08 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139526870 | CMS |
| AstraZeneca Pharmaceuticals LP | $111.48 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104349658 | CMS |
| AstraZeneca Pharmaceuticals LP | $125.03 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104283135 | CMS |
| GlaxoSmithKline, LLC. | $20.22 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116267085 | CMS |
| Janssen Pharmaceuticals, Inc | $116.74 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1077983378 | CMS |
| Merck Sharp & Dohme LLC | $14.89 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141605814 | CMS |
| Novo Nordisk Inc | $18.67 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100342248 | CMS |
| Novo Nordisk Inc | $17.02 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100601087 | CMS |
| Teva Pharmaceuticals USA, Inc. | $123.15 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151612946 | CMS |
| Xeris Pharmaceuticals, Inc. | $21.91 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144631003 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.